Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

Addgene

MED12_pLX307 Citations (2)

Originally described in: Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in beta-Catenin-Active Cancers.
Rosenbluh J, Mercer J, Shrestha Y, Oliver R, Tamayo P, Doench JG, Tirosh I, Piccioni F, Hartenian E, Horn H, Fagbami L, Root DE, Jaffe J, Lage K, Boehm JS, Hahn WC Cell Syst. 2016 Sep 28;3(3):302-316.e4. doi: 10.1016/j.cels.2016.09.001. PubMed Journal

Articles Citing MED12_pLX307

Articles
XLID syndrome gene Med12 promotes Ig isotype switching through chromatin modification and enhancer RNA regulation. Haque F, Honjo T, Begum NA. Sci Adv. 2022 Nov 25;8(47):eadd1466. doi: 10.1126/sciadv.add1466. Epub 2022 Nov 25. PubMed
Exosomal transfer of miR-548aq-3p confers cisplatin resistance via MED12 downregulation in epithelial ovarian cancer. Shi Y, Zou Y, Guo Y, Liu Y, Wang Q. Am J Cancer Res. 2023 May 15;13(5):1999-2012. eCollection 2023. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.